ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2006

Primary Completion Date

February 1, 2008

Study Completion Date

February 1, 2008

Conditions

Fallopian Tube NeoplasmsPeritoneal NeoplasmsOvarian Neoplasms

Interventions

DRUG

ABI-007

80mg/m\^2 to 150mg/m\^2 IV every 3 weeks

DRUG

Carboplatin

6 AUC IV every 3 weeks on the same day as ABI-007

Trial Locations (1)

University of Texas, MD Anderson Cancer Center, Houston